Quality of life has become a very important parameter in benign prostatic hyperplasia (BPH) and one of the major concepts identified by the patients to be important is related to sexuality after BPH therapy. The impact on sexuality resulting from the various treatment modalities of BPH, either medical, surgical or instrumental has been too often neglected in the past and poorly investigated. The present article reviews the influence on sexual function of current therapies for symptomatic BPH.

Walsh PC: Benign prostatic hyperplasia. In Campbell’s Urology (6th ed, Walsh PC et al, editors). WB Saunders, Philadelphia, 1992, pp l007–1027.
Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL: Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997;31(3):272–280.
Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrickson M, Göthberg M, Steineck G: Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: A population-based study. Age Ageing 1996;25:285–291.
Schou J, Holm NR, Meyhoff HH: Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1996;179:119–122.
Nickel JC: Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 1998;81(3):383–387.
Barry MJ, Adolfsson J, Batista JE, Bosch JLHR, Corica A, Donovan J, Jonas U, Lobel B, Lukacs B, Mortensen S, O’Leary M, Richard F, Schmidt JD, Tsukamoto T, Zattoni F: Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In the Proceedings of the 4th international consultation on benign prostatic hyperplasia (BPH), pp 267–321, L. Denis et al, Editors, S.C.I., 1997.
Marberger MJ: Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. Urology 1998;51:677–686.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 1998;338:557–563.
Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. NEJM 1996;335:553–559.
Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29(4):231–240.
Lukacs B, Léplège A, Thibault P, Jardin A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731–740.
Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997;31(2):190–198.
Jardin A, Debruyne FMJ, McCarthy C and the Alfin study group: Sexual function in men with BPH treated either with an alpha adrenergic blocker, Alfuzosin or the alpha-reductase inhibitor, Finasteride, or the combination: A European randomized study in 1,051 patients. J Urol 1998;159(suppl): Abstract 1271.
Schulman CC, Lock T, Buzelin JM and the European Tamsulosin group: Tamsulosin: 3-year follow-up of efficacy and safety in 516 patients with LUTS suggestive of BPO. J Urol 1998;159(suppl): Abstract 983.
Chapple CR, Wyndaele Jj, Nording J, Boeminghaus F, Ypma AFGVM, Abrams P: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. Eur Urol 1996;29:155–167.
Abrams P, Schulman CC, Vaage S, and the European Tamsulosin group: Tamsulosin, a selective alpha1c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). Br J Urol 1995;76:325–336.
Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in begnin prostatic hyperplasia. Urology 1998;51:892–900.
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, Padley RJ: The hytrin community assessment trial study (HYCAT): A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996;47:159–168.
Puente JG, Swooney M, Cary MM, Roerhrborn C for the PREDICT investigators: Relationship between age, lower urinary tract symptoms (LUTS) and various domains of erectile dysfunction in 1,098 patients with BPH in the PREDICT study. J Urol 1998;159(suppl): Abstract 1272.
Walsh PC: Transurethral resection of the prostate. In Campbell’s Urology (7th edition, Walsh PC et al, eds). WB Saunders Editors, Philadelphia, 1998, pp 1511–1522.
Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332:75–79.
Mebust WK, et al: Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of thirteen participating institutions evaluating 3,885 patients. J Urol 1989;141:243–247.
Hammadeh MY, Madaan S, Singh M, Philp T: Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol 1998;34(3):188–192.
Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC: Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995;45:768–775.
Kinn AC, Helmy-Dhejne C, Larsson J: Sexual function one year after transurethral prostatic resection. Patients’ own assessments. Scand J Urol Nephrol 1998;32:33–35.
Schulman CC and Zlotta AR: Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1995;45:28–33.
Arai Y, Kazutoshi O, Takashi O, Shinya M, Yoshitaka A, Hiroshi M: Interstitial laser coagulation for management of benign prostatic hyperplasia: A Japanese experience. J Urol 1998;159:1961–1965.
De la Rosette JJMCH, Muschter R, Lopez MA, Gilliatt D: Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode-laser system with temperature feedback. Br J Urol 1997;80:433–438.
Perlmutter AP, Muschter R: Interstitial laser prostatectomy. Mayo Clin Proc 1998;73:903–907.
Francisca EAE, d’Ancona FCH, Hendriks JCM, Kiemeney LALM, Debruyne FMJ, De la Rosette JJMCH: Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0): Results of a randomized transurethral microwave thermotherapy versus sham study. J Urol 1997;158:1839–1844.
Steele GS and Sleep DJ: Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997;158:1834–1838.
Campo B, Bergamaschi F, Corrada P and Ordesi G: Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997;49:847–850.
Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP and Oesterling JE: A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998;159:1588–1594.
Issa MM and Oesterling JE: Transurethral needle ablation (TUNATM): an overview of radiofrequency thermal therapy for the treatment of benign prostatic hyperplasia. Current Opinion in Urology 1996;6:20–27.
Dixon CM: Transurethral needle ablation for the treatment of benign prostatic hyperplasia. Urologic Clinics of North America 1995;22:441.
Roehrborn CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R, Shumaker BP and Narayan P: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urol 1998;51:415–421.
Gillenwater JY, Conn RL, Chrysant SG, et al for the Multicenter Study group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essentiel hypertension. A double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995;154:110–115.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.